Mast Therapeutics (MSTX) Reports In-Line Q1 Loss of 6c/Share

Mast Therapeutics (NYSE: MSTX) reported Q1 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Envoy Medical (COCH) PT Lowered to $2 at H.C. Wainwright
• CrowdStrike (CRWD) PT Lowered to $227 at Scotiabank